author-photo

Adrian Bot

MannKind Corporation

233

Papers

6574

Citations

Citation Trend

Filter By

Papers (165) Sort By

Journal Conference Others

Long-Term (≥4 Year and ≥5 Year) Overall Survival (OS) By 12- and 24-Month Event-Free Survival (EFS): An Updated Analysis of ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Refractory Large B-Cell Lymphoma (LBCL)

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Long-Term Survival and Gradual Recovery of B Cells in Patients (Pts) with Refractory Large B Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel (Axi-Cel)

2021
Show All
- Source
- Cite
- Save
Citations (1)
Abstract CT036: Axicabtagene ciloleucel (axi-cel) product attributes and immune biomarkers associated with clinical outcomes in patients (pts) with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) in ZUMA-5

2021 Clinical Trials
Show All
- Source
- Cite
- Save
Citations (2)
A Phase II Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results.

2021 Blood
Show All
- Source
- Cite
- Save
Citations (7)
Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma.

2021 British Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (0)
Mechanisms of Antigen Escape: Discovery of a Novel CD19 Point Mutation That Renders Leukemic Tumor Cells Resistant to Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy

2021
Show All
- Source
- Cite
- Save
Citations (0)
Prediction of Early Onset Cytokine Release Syndrome and Neurologic Events after Axicabtagene Ciloleucel in Large B-Cell Lymphoma Based on Machine Learning Algorithms

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Abstract CT166: Pretreatment (PreTx) immune cell phenotypes in peripheral blood associated with the tumor immune contexture, product attributes, and durable clinical efficacy in patients with large B-cell lymphoma (LBCL) treated with axicabtagene ciloleucel (axi-cel)

2021 Clinical Trials
Show All
- Source
- Cite
- Save
Citations (0)
TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers.

2021 Nature Medicine
Show All
- Source
- Cite
- Save
Citations (19)